Atrion (ATRI) Downgraded to “Strong Sell” at BidaskClub

BidaskClub downgraded shares of Atrion (NASDAQ:ATRI) from a sell rating to a strong sell rating in a report published on Monday morning.

Atrion (ATRI) opened at $639.90 on Monday. The firm has a market capitalization of $1,189.90, a price-to-earnings ratio of 38.18 and a beta of 0.85. Atrion has a twelve month low of $454.10 and a twelve month high of $694.00.

Atrion (NASDAQ:ATRI) last posted its quarterly earnings data on Wednesday, November 8th. The medical instruments supplier reported $4.29 EPS for the quarter. The firm had revenue of $37.90 million during the quarter. Atrion had a return on equity of 18.34% and a net margin of 22.98%.

The firm also recently declared a quarterly dividend, which was paid on Friday, December 15th. Shareholders of record on Friday, December 1st were paid a $1.20 dividend. The ex-dividend date was Thursday, November 30th. This represents a $4.80 dividend on an annualized basis and a yield of 0.75%. Atrion’s payout ratio is presently 26.59%.

A number of hedge funds have recently modified their holdings of the business. BNP Paribas Arbitrage SA grew its position in shares of Atrion by 4,800.0% during the second quarter. BNP Paribas Arbitrage SA now owns 196 shares of the medical instruments supplier’s stock valued at $126,000 after purchasing an additional 192 shares in the last quarter. Legal & General Group Plc grew its position in shares of Atrion by 4.3% during the second quarter. Legal & General Group Plc now owns 336 shares of the medical instruments supplier’s stock valued at $216,000 after purchasing an additional 14 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of Atrion by 17.7% during the second quarter. Victory Capital Management Inc. now owns 438 shares of the medical instruments supplier’s stock valued at $282,000 after purchasing an additional 66 shares in the last quarter. Capital Analysts LLC purchased a new position in shares of Atrion during the second quarter valued at about $434,000. Finally, Voya Investment Management LLC grew its position in shares of Atrion by 10.2% during the second quarter. Voya Investment Management LLC now owns 755 shares of the medical instruments supplier’s stock valued at $486,000 after purchasing an additional 70 shares in the last quarter. Institutional investors and hedge funds own 59.01% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Atrion (ATRI) Downgraded to “Strong Sell” at BidaskClub” was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.com-unik.info/2017/12/22/atrion-atri-downgraded-to-strong-sell-at-bidaskclub.html.

Atrion Company Profile

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit